Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 17/20 | 0.83 |
| ▸ | ADAM17 | P78536 | 15/20 | 0.83 |
| ▸ | MMP8 | P22894 | 2/20 | 0.62 |
| ▸ | MMP3 | P08254 | 1/20 | 0.62 |
| ▸ | MMP13 | P45452 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7220235 | 1.00 | MMP1 (0.83) | MMP1ADAM17MMP8MMP3MMP13 | |
| SCHEMBL7221296 | 0.91 | MMP1 (1.00) | MMP1ADAM17MMP8MMP3MMP13 | |
| SCHEMBL7220119 | 0.91 | MMP1 (1.00) | MMP1ADAM17MMP8MMP3MMP13 | |
| SCHEMBL8433179 | 0.89 | ADAM17 (0.68) | MMP1ADAM17MMP13 | |
| SCHEMBL5757960 | 0.89 | ADAM17 (1.00) | MMP1ADAM17MMP8MMP3MMP13 | |
| SCHEMBL5757799 | 0.89 | ADAM17 (1.00) | MMP1ADAM17MMP8MMP3MMP13 | |
| SCHEMBL5757113 | 0.89 | ADAM17 (1.00) | MMP1ADAM17MMP8MMP3MMP13 | |
| SCHEMBL5758134 | 0.86 | MMP1 (0.79) | MMP1ADAM17MMP8MMP3MMP13 | |
| SCHEMBL8436365 | 0.84 | ADAM17 (0.72) | MMP1ADAM17MMP8MMP3MMP13 | |
| SCHEMBL8432178 | 0.82 | ADAM17 (0.58) | MMP1ADAM17MMP3MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0935963-A2 | The use of MMP-13 selective inhibitors for the treatment of osteoarthritis and other matrix metalloproteinase-mediated disorders | Pfizer Products Inc. (US) | 1999-08-18 | — | — | EP | claimed |
| US-6599890-B1 | Inhibitors of matrix metalloproteinases or the production of tumor necrosis factor | PFIZER INC | 2003-07-29 | — | — | US | disclosed |
| EP-0960098-A1 | ARYLSULFONYL HYDROXAMIC ACID DERIVATIVES | PFIZER INC. (US) | 1999-12-01 | — | — | EP | disclosed |
| EP-0935963-A2 | The use of MMP-13 selective inhibitors for the treatment of osteoarthritis and other matrix metalloproteinase-mediated disorders | Pfizer Products Inc. (US) | 1999-08-18 | — | — | EP | disclosed |
| WO-1998034918-A1 | ARYLSULFONYL HYDROXAMIC ACID DERIVATIVES | PFIZER INC. (US) | 1998-08-13 | — | — | WO | disclosed |